(Q57697548)

English

Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques

article

In more languages

Statements

scholarly article

0 references

Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques (English)

0 references

1 reference

based on heuristic

inferred from title

post-exposure prophylaxis

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

David C. Montefiori

9

object named as

David C. Montefiori

0 references

Flavia Ferrantelli

object named as

Flavia Ferrantelli

1

0 references

Regina Hofmann-Lehmann

object named as

Regina Hofmann-Lehmann

8

0 references

author name string

Kathleen A. Buckley

2

0 references

Robert A. Rasmussen

3

0 references

Alistair Chalmers

4

0 references

Tao Wang

5

0 references

Pei-Lin Li

6

0 references

Alison L. Williams

7

0 references

Lisa A. Cavacini

10

0 references

Hermann Katinger

11

0 references

Gabriela Stiegler

12

0 references

Daniel C. Anderson

13

0 references

Harold M. McClure

14

0 references

Ruth M. Ruprecht

15

0 references

language of work or name

0 references

publication date

February 2007

0 references

0 references

358

0 references

1

0 references

69-78

0 references

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Mucosal immunity: integration between mother and the breast-fed infant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Neutralizing antibodies against HIV -- back in the major leagues?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Antibodies: can they protect against HIV infection?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2006.07.056

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57697548&oldid=1648103655"